RSS Search

News  Feeds  Tags  Search Shortcuts

FeedsFarm.com > Aspreva Announces Completion of Patient Enrolment in Phase III Clinical Trial for CellCept in Myasthenia Gravis

Aspreva Announces Completion of Patient Enrolment in Phase III Clinical Trial for CellCept in Myasthenia Gravis

29th Nov 2005, 01:15 GMT

Aspreva Pharmaceuticals Corp, an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, announced completion of enrolment of 176 patients in the phase III clinical study to assess the safety and efficacy of mycophenolate mofetil (MMF or CellCept ) to maintain or improve symptom control with reduced corticosteroids in patients with myasthenia gravis.

View full story at www.myhealthcarenews.com

Aspreva Announces Completion of Patient Enrolment in Phase III Clinical Trial for CellCept in Myasthenia Gravis related news:

Latest news from StratWire - Business of Healthcare NewsFeed: